Global Breast Cancer Liquid Biopsy
Market Report
2024
breast cancer liquid biopsy market was valued at USD 294.34 million in 2022 and is projected to reach USD 1481.65 million by 2030, registering a CAGR of 22.4% for the forecast period 2023- 2030.
The base year for the calculation is 2023 and 2019 to 2023 will be historical period. The year 2024 will be estimated one while the forecasted data will be from year 2025 to 2031. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
Share your contact details to receive free updated sample copy/pages of the recently published edition of Breast Cancer Liquid Biopsy Market Report 2024.
The global breast cancer liquid biopsy market was valued at USD 294.34 million in 2022 and is projected to reach USD 1481.65 million by 2030, registering a CAGR of 22.4% for the forecast period 2023- 2030.
Base Year | 2023 |
Historical Data Time Period | 2019-2023 |
Forecast Period | 2024-2031 |
Global Breast Cancer Liquid Biopsy Market Sales Revenue 2020 | $ 7643.49 Million |
Global Breast Cancer Liquid Biopsy Market Sales Revenue 2030 | $ 13988.7 Million |
Global Breast Cancer Liquid Biopsy Market Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 6.95% |
Market Split by Circulating Biomarker |
|
Market Split by Application |
|
List of Competitors |
|
Regional Analysis |
|
Country Analysis |
|
Key Qualitative Information Covered |
|
Report scope is customizable as we have a huge database of Breast Cancer Liquid Biopsy industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Breast Cancer Liquid Biopsy Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Breast cancer liquid biopsy is a non-invasive diagnostic method for finding and examining breast cancer-related biomarkers in a patient's blood or other bodily fluids. It entails the gathering of a liquid sample, usually blood, and the examination of particular elements within that sample to find genetic mutations, changes, or other biomarkers connected to breast cancer. For breast cancer, circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) are the main targets of liquid biopsy studies. Cancer cells (CTCs) are cancer cells that have broken out from the original tumor and migrated into the circulation. Cancer cells that are on their way to dying leak pieces of their tumor DNA into the blood. These elements can reveal important details about the presence and traits of breast cancer.
Breast cancer is a common type of cancer that develops in the breast tissue. It is one of the main reasons for cancer-related mortality in women around the world. Over the past few decades, there has been an increase in the occurrence of breast cancer. According to the World Health Organisation, 2.3 million women were diagnosed with breast cancer in 2020, and there were 685,000 deaths worldwide. In addition, according to Springer Nature Limited, Breast cancer (BC) affects 1 in every 8 women in the United States and is currently the most prevalent cancer worldwide.
There is hope despite the rising incidence of breast cancer. The survival rates for breast cancer are rising due to early detection and treatment. Breast cancer patients frequently receive advanced treatment and go on to healthy lives. The increasing prevalence of breast cancer creates a greater need for accurate and efficient diagnostic methods to detect, monitor, and manage the disease. Breast cancer liquid biopsy refers to a non-invasive diagnostic technique used to detect and analyze biomarkers associated with breast cancer in a patient's blood or other body fluids.
Liquid biopsy faces competition from other well-established and newly developed breast cancer diagnostic procedures, including mammography, tissue biopsies, and other molecular diagnostic tools. It may be difficult for liquid biopsy to capture a sizable portion of the market if these alternatives already have well-established infrastructure, clinical guidelines, and reimbursement systems.
At the outset of the COVID-19 pandemic in the spring of 2020, many breast imaging and diagnostic practices purposefully halted mammographic screening to minimize patient and staff exposure to the virus. According to the Radiological Society of North America, reports found that the recommendation of biopsies decreased precipitously in April 2020 compared with April 2019 (76% decrease, 236 biopsies recommended in 2020 vs 1000 recommended in 2019). So, the COVID-19 pandemic has had a negative impact on the breast biopsy market.
We have various report editions of Breast Cancer Liquid Biopsy Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
mDETECT Launched Breast Cancer Liquid Biopsy Clinical Trial
mDETECT Inc. a liquid biopsy company based on DNA methylation announced that Dr. Christopher Mueller, Professor at the Cancer Research Institute of Queen’s University and founder of mDETECT-Inc, was recently awarded a $900k grant from the Canadian Institute of Health Research (CIHR).
Liquid Biopsy Assay Expanded its offerings to Include MRD, Disease Recurrence Detection in Early-Stage Breast and Lung Cancer
The Guardant Reveal assay has been expanded for the detection of minimal residual disease (MRD) and disease recurrence in patients with early-stage breast cancer and lung cancer, according to an announcement from Guardant Health Inc.
Top Companies Market Share in Breast Cancer Liquid Biopsy Industry: (In no particular order of Rank)
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
The development of liquid biopsy technology has been led by North America, most specifically the United States. The area offers a strong infrastructure for medical innovation, research, and development. The development and marketing of liquid biopsy products are sped up by the presence in North America of numerous top biotechnology and diagnostic businesses with competence in liquid biopsy technologies. In addition, the adoption and application of sophisticated diagnostic methods are supported by the region's well-developed healthcare infrastructure. With regard to breast cancer diagnosis and treatment, the area is home to a significant number of hospitals, research facilities, and specialized cancer centers. Liquid biopsy as a diagnostic option is more likely to be adopted and provided by these institutions.
The current report Scope analyzes Breast Cancer Liquid Biopsy Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
The above graph is for illustrative purposes only. To learn more about geographical trends request the free sample pages. Contact US!
Global Breast Cancer Liquid Biopsy Market Report 2024 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Breast Cancer Liquid Biopsy Industry growth. Breast Cancer Liquid Biopsy market has been segmented with the help of its Circulating Biomarker, Application , and others. Breast Cancer Liquid Biopsy market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
cfDNA is genetic material released by cells, including tumor cells, into the bloodstream. A patient's blood sample can be used to isolate and analyze cfDNA using liquid biopsy procedures. By analyzing cfDNA, liquid biopsies provide a non-invasive alternative to conventional tissue biopsies for the detection and surveillance of breast cancer. Mutations, amplifications, deletions, and rearrangements that are unique to tumor cells can all be found in cfDNA. These modifications sometimes referred to as somatic mutations, can be found and examined using liquid biopsy techniques. Liquid biopsy can offer useful knowledge on the genetic composition of a tumor, including possible therapeutic targets and resistance mechanisms, by profiling cfDNA.
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Breast Cancer Liquid Biopsy Industry. Request a Free Sample PDF!
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities for each application of Breast Cancer Liquid Biopsy from 2019 to 2031. This will also help to analyze the demand for Breast Cancer Liquid Biopsy across different end-use industries. Our research team will also help acquire additional data such as Value Chain, Patent analysis, Company Evaluation Quadrant (Matrix), and much more confidential analysis and data insights.
Some of the key Application of Breast Cancer Liquid Biopsy are:
The above Graph is for representation purposes only. This chart does not depict actual Market share. Please purchase the Breast Cancer Liquid Biopsy market report 2024 Edition by contacting our team.
Research Associate at Cognitive Market Research
Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.
Anushka is a highly motivated and detail-oriented research analyst with a passion for uncovering valuable insights from data. Her expertise in Market Research and business intelligence has equipped her with the skills necessary to analyze complex information and provide strategic recommendations. She thrives in dynamic environments where her analytical abilities and research expertise can contribute to informed decision-making for businesses
I played a pivotal role in conducting market research and competitive analysis. I have a demonstrated ability to synthesize diverse data sources, identify trends, and translate findings into actionable recommendations. My collaborative approach facilitated effective communication of insights, fostering a data-driven culture within the organization. I am committed to maintaining excellence through continuous learning and staying ahead of industry trends. Regular participation in conferences and professional development opportunities keeps my skills sharp and relevant.
Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.
The Global Breast Cancer Liquid Biopsy Market is witnessing significant growth in the near future.
In 2023, the Circulating Tumor Cells (CTCs) segment accounted for noticeable share of global Breast Cancer Liquid Biopsy Market and is projected to experience significant growth in the near future.
The Reference Laboratories segment is expected to expand at the significant CAGR retaining position throughout the forecast period.
Some of the key companies QIAGEN , The Menarini Group and others are focusing on its strategy building model to strengthen its product portfolio and expand its business in the global market.
Disclaimer:
Circulating Biomarker | Circulating Tumor Cells (CTCs), Cell-free DNA (cfDNA), Extracellular Vesicles (EVs), Other |
Application | Reference Laboratories, Hospitals and Physician Laboratories, Other |
List of Competitors | QIAGEN, NeoGenomics Laboratories, The Menarini Group, Biocept Inc., F. Hoffmann-La Roche Ltd., Sysmex Corporation, Epic Sciences Inc., Myriad Genetics Inc., Fluxion Biosciences Inc., Illumina, Bio-Rad Laboratories, Myriad Genetics, Cynvenio, Biosystems Inc., Genomic Health Inc., Thermo Fisher Scientific Inc., Fluxion Biosciences Inc., Biodesix Inc., Guardant Health Inc., Isogen Life Science B.V., others. |
This chapter will help you gain GLOBAL Market Analysis of Breast Cancer Liquid Biopsy. Further deep in this chapter, you will be able to review Global Breast Cancer Liquid Biopsy Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
Chapter 2 North America Market Analysis
Purchase Add-Ons to Customize the Report Edition and get further granular data level data about the North America market. Add-On Cost: Request before placing the order, Respective Pricing will be informed after sending the inquiry
Qualitative Analysis for the North America Market: North America Breast Cancer Liquid Biopsy Market Trends North America Breast Cancer Liquid Biopsy Technological Road Map North America Breast Cancer Liquid Biopsy Market Drivers North America Breast Cancer Liquid Biopsy Market Restraints North America Breast Cancer Liquid Biopsy Market Opportunity Market Attractiveness Analysis COVID – 19 Impact Analysis PESTEL Analysis Porter’s Five Forces Analysis Product Life Cycle Industrial Chain Analysis
You can purchase only the Executive Summary North America Market (2019 vs 2024 vs 2031)
Chapter 3 Europe Market Analysis
You can purchase only the Executive Summary Europe Market (2019 vs 2024 vs 2031)
Chapter 4 Asia-Pacific Market Analysis
You can purchase only the Executive Summary Asia Pacific Market (2019 vs 2024 vs 2031)
Chapter 5 South America Market Analysis
You can purchase only the Executive Summary South America Market (2019 vs 2024 vs 2031)
Chapter 6 Middle East and Africa Market Analysis
You can purchase only the Executive Summary Middle East and Africa Market (2019 vs 2024 vs 2031)
Only Available with Corporate User License
Chapter 7 Top 10 Countries Analysis
Competitor's Market Share and Revenue (Subject to Data Availability for Private Players)
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
(Subject to Data Availability (Private Players))
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Chapter 9 Qualitative Analysis (Subject to Data Availability)
Segmentation Circulating Biomarker Analysis 2019 -2031, will provide market size split by Circulating Biomarker. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Circulating Biomarker Analysis 2019 -2031
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by Application Analysis 2019 -2031
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Breast Cancer Liquid Biopsy market
Chapter 12 Research Findings
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
Why Circulating Tumor Cells (CTCs) have a significant impact on Breast Cancer Liquid Biopsy market? |
What are the key factors affecting the Circulating Tumor Cells (CTCs) and Cell-free DNA (cfDNA) of Breast Cancer Liquid Biopsy Market? |
What is the CAGR/Growth Rate of Reference Laboratories during the forecast period? |
By type, which segment accounted for largest share of the global Breast Cancer Liquid Biopsy Market? |
Which region is expected to dominate the global Breast Cancer Liquid Biopsy Market within the forecast period? |
Segmentation Level Customization |
|
Global level Data Customization |
|
Region level Data Customization |
|
Country level Data Customization |
|
Company Level |
|
Additional Data Analysis |
|
Additional Qualitative Data |
|
Additional Quantitative Data |
|
Service Level Customization |
|
Report Format Alteration |
|
Published Report Editions
are Just a Tip of an Iceberg
Access the Complete Database of
Breast Cancer Liquid Biopsy Market
Request Sample